Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with ...

Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand ...

The UK’s voluntary scheme for branded medicines pricing, access and growth (known as VPAG) makes sure that the NHS does not ...

Tesla’s board is giving Chief Executive Elon Musk a $23.7 billion stock award —so long as he stays focused on the company.

Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Tánaiste Simon Harris has said the introduction of the new US tariff on EU goods provides "some degree of certainty" to businesses.

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.